Physician profile
Simon Wu
NPI 1437393865
$1,370.63
in general payments reported to CMS, 2019-2025
15 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $125 · 2021: $249 · 2022: $174 · 2023: $244 · 2024: $169 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $393.07 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $206.83 | 2019-2021 | |
| Alcon Vision LLC | $145.31 | 2021-2025 | Simbrinza, Clareon, Ilux |
| Eyevance Pharmaceuticals LLC | $134.89 | 2020-2022 | |
| Biotissue Holdings INC. | $113.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $71.42 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $60.96 | 2024-2025 | Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.69 | 2019-2020 | |
| Shire North American Group INC | $39.74 | 2019 | |
| Allergan, INC. | $38.54 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $30.03 | 2025 | Xdemvy |
| Dompe US, INC. | $27.26 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $20.76 | 2022 | |
| Abbvie INC. | $16.01 | 2023 | Lumigan, Alphagan P |
| Harrow Eye, LLC | $15.57 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.